Skin Therapy Letter

The latest research and treatments in the science of #dermatology. The Dermatology Edition is indexed by the US National Library of Medicine.

[Skin Therapy Letter @S_TherapyLetter]

Advances in the Management of Hyperhidrosis
https://t.co/2ECVmz0rVQ

[Skin Therapy Letter @S_TherapyLetter]

Latest articles from Skin Therapy Letter - Vol 31.2

https://t.co/ENvcSSCbHs

[Skin Therapy Letter @S_TherapyLetter]

Topical Ruxolitinib for the Treatment of Hidradenitis Suppurativa

https://t.co/ZS0hf2Huim

[Skin Therapy Letter @S_TherapyLetter]

OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data
https://t.co/Mu5tQP7LOn

[Skin Therapy Letter @S_TherapyLetter]

Latest articles from Skin Therapy Letter - Vol 30.6
https://t.co/GDE8ArynfF

[Skin Therapy Letter @S_TherapyLetter]

Latest articles from Skin Therapy Letter - Vol 30.2 https://t.co/pUlmT5LXQQ

[Skin Therapy Letter @S_TherapyLetter]

This marks the second FDA-approved treatment for NF and the first approved therapy for adults.

https://t.co/GFmfY45hfA

[Skin Therapy Letter @S_TherapyLetter]

Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™) was approved in Feb to treat adult and pediatric patients ≥2 years of age with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.

[Skin Therapy Letter @S_TherapyLetter]

Update on Drugs & Devices: March-April 2025
https://t.co/GFmfY45hfA

[Skin Therapy Letter @S_TherapyLetter]

Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab’s Efficacy and Utilization
https://t.co/3nvN48pwET

[Skin Therapy Letter @S_TherapyLetter]

Roflumilast for the Treatment of Seborrheic Dermatitis: A Review
https://t.co/swXlGotIMY

[Skin Therapy Letter @S_TherapyLetter]

An Update on the Clinical Management of Cutaneous Leishmaniasis
https://t.co/2Mz6yZiCfM

[Skin Therapy Letter @S_TherapyLetter]

Pediatric Hidradenitis Suppurativa: An Overview
https://t.co/486VM2bood

[Skin Therapy Letter @S_TherapyLetter]

A Review of the Role and Treatment of Biofilms in Skin Disorders
https://t.co/K5hL1NtG1N

[Skin Therapy Letter @S_TherapyLetter]

A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention
https://t.co/yM4OFaB1mm

[Skin Therapy Letter @S_TherapyLetter]

Enhancing Bioavailability: Advances in Oral Isotretinoin Formulations
https://t.co/SYpVkFQfdB

[Skin Therapy Letter @S_TherapyLetter]

An Overview on the Management of Atrophic Acne Scars: The Role of Trifarotene as an Adjunct

https://t.co/QDWXk8tQFB

[Skin Therapy Letter @S_TherapyLetter]

Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis

https://t.co/RKRlyAuQ2v

[Skin Therapy Letter @S_TherapyLetter]

A Review of the Use of Intravenous Immunoglobulin Therapy in Dermatology
https://t.co/TwIqPGPKUH

[Skin Therapy Letter @S_TherapyLetter]

An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa

https://t.co/aV5rlF4tlC